Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Department of Pediatrics, Boston Medical Center, Boston, MA, USA.
J Med Eng Technol. 2023 Nov;47(8):371-375. doi: 10.1080/03091902.2024.2343682. Epub 2024 May 8.
Access to medical technologies is a critical component of universal access to care; however, the advancement of technologies for children has historically lagged behind those for adults. The small market size, anatomic and physiologic variability, and legal and ethical implications pose unique barriers to developing and commercialising paediatric biomedical innovations. These challenges are magnified in low-resource settings (LRS), which often lack appropriate regulatory oversight, support for service contracts, and supply chain capacity. The COVID-19 pandemic exposed shortcomings in the traditional industry model for medical technologies, while also catalysing open-source approaches to technology development and dissemination. Open-source pathways - where products are freely licenced to be distributed and modified - addressed key shortages in critical equipment. Relatedly, we argue that open-source approaches can accelerate paediatric global health technology development. Open-source approaches can be tailored to clinical challenges independent of economic factors, embrace low-cost manufacturing techniques, and can be highly customisable. Furthermore, diverse stakeholders, including families and patients, are empowered to participate in collaborative communities of practice. How to regulate the development, manufacture, and distribution of open-source technologies remains an ongoing area of exploration. The need for democratised innovation must be carefully balanced against the imperatives of safety and quality for paediatric-specific solutions. This can be achieved, in part, through close coordination between national regulatory agencies and decentralised networks where products can be peer-reviewed and tested. Altogether, there is significant potential for open source to advance more equitable and sustainable medical innovations for all children.
获取医疗技术是实现普遍获得医疗服务的关键组成部分;然而,儿童医疗技术的发展历史上一直落后于成人医疗技术。儿童市场规模小、解剖和生理变异性、以及法律和伦理问题,这些都给开发和商业化儿科生物医学创新带来了独特的障碍。这些挑战在资源匮乏环境(LRS)中更为突出,这些环境通常缺乏适当的监管监督、服务合同支持和供应链能力。COVID-19 大流行暴露了医疗技术传统行业模式的缺陷,同时也催化了技术开发和传播的开源方法。开源途径 - 产品可以免费许可分发和修改 - 解决了关键设备的关键短缺问题。相关地,我们认为开源方法可以加速儿科全球卫生技术的发展。开源方法可以针对独立于经济因素的临床挑战进行定制,采用低成本制造技术,并具有高度的可定制性。此外,包括家庭和患者在内的各种利益相关者都有能力参与协作实践社区。如何监管开源技术的开发、制造和分发仍然是一个正在探索的领域。民主化创新的需求必须与儿科特定解决方案的安全性和质量要求谨慎平衡。这可以部分通过国家监管机构之间的密切协调以及产品可以进行同行评审和测试的去中心化网络来实现。总之,开源技术有很大的潜力为所有儿童推进更公平和可持续的医疗创新。